It’s only fair to share… Clofutriben Cas 1204178-50-6 HCL 1203941-88-1 Molecular Weight 424.80 Formula C19H16ClF3N4O2 Clofutriben (ASP3662) is a 11β-hydroxysteroid dehydrogenase type 1 inhibitor. Clofutriben is an orally bioavailable selective inhibitor of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1; 11bHSD1; HSD11B1; HSD1; HSD-1), with potential protective activity for disorders of corticosteroid excess. Upon oral administration, …
Author archives
Pirtobrutinib
It’s only fair to share… Pirtobrutinib 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide FDA 2023, 1/27/2023, Jaypirca To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitorDrug Trials Snapshot Pirtobrutinib, sold under the brand name Jaypirca, is an anticancer medication that is used to treat mantle cell lymphoma.[1][2][4] It inhibits B cell …
Clesacostat
It’s only fair to share… Clesacostat PF 05221304, 752DF9PPPI CAS 1370448-25-1 WeightAverage: 502.571Monoisotopic: 502.221620082 Chemical FormulaC28H30N4O5 4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4′-piperidine]-1′-carbonyl)pyridin-2-yl]benzoic acid Clesacostat is under investigation in clinical trial NCT04321031 (Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)). CLESACOSTAT is a small molecule drug with a maximum clinical trial phase of II (across all indications) and has …
Civorebrutinib
It’s only fair to share… Civorebrutinib WS-413, 933NK55FMX 5-amino-3-[4-(5-chloropyridin-2-yl)oxyphenyl]-1-[(6R)-4-cyano-4-azaspiro[2.5]octan-6-yl]pyrazole-4-carboxamide Molecular Weight 463.92 Formula C23H22ClN7O2 CAS No. 2155853-43-1 Civorebrutinib (WS-413) is a Bruton’s tyrosine kinase inhibitor with antineoplastic effect. Scheme Patent Zhejiang Yukon Pharma Co., Ltd. WO2017198050 WO2019091440 WO2019091438 PATENT WO2019091441 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019091441&_cid=P10-MADPL7-76599-1 Example 1 [0116]Preparation of (R)-5-amino-3-(4-((5-chloropyridin-2-yl)oxy)phenyl)-1-(4-cyano-4-azaspiro[2.5]octan-6-yl)-1H-pyrazole-4-carboxamide (Compound 1) Step 1 [0119] [0120]DIPEA (185 g, 1.44 …
Cinsebrutinib
It’s only fair to share… Cinsebrutinib CAS 2724962-58-5 2-fluoro-1-[(3S)-1-prop-2-enoylpiperidin-3-yl]-5,6,7,8,9,10-hexahydrocyclohepta[b]indole-4-carboxamide Molecular Weight 383.46 Formula C22H26FN3O2 7BS8743F3E CINSEBRUTINIB is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication. Cinsebrutinib is a Bruton’s tyrosine kinase inhibitor, extracted from patent WO2021207549 (compound 5-6). Cinsebrutinib has the potential for cancer study. SCHEME INTERMEDIATE MAIN SYN example …
Ceralasertib
It’s only fair to share… Ceralasertib CAS 1352226-88-0 (R)-imino(methyl)(1-{6-[(3R)-3-methylmorpholin-4-yl]-2-{1H-pyrrolo[2,3-c]pyridin-4-yl}pyrimidin-4-yl}cyclopropyl)-lambda6-sulfanone imino-methyl-[1-[6-[(3R)-3-methylmorpholin-4-yl]-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl]cyclopropyl]-oxo-λ6-sulfane UNII 85RE35306Z Molecular Weight 412.51 Formula C20H24N6O2S AZD 6738, ATR KINASE INHIBITOR AZD6738, AZD-6738, AZD6738, WHO 10842 Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of ATR kinase with an IC50 of 1 nM. Ceralasertib is an investigational new drug that is being evaluated for the treatment of cancer.[1] It is an ATR …
CEFILAVANCIN
It’s only fair to share… CEFILAVANCIN, TD-1792 CAS 722454-12-8 C87H96Cl3N16O28S2, 1984.28 F76229E21M Vancomycin, 26-[[[3-[[(Z)-[1-(2-amino-5-chloro-4-thiazolyl)-2-[[(6R,7R)-2-carboxy-8-oxo-3-(pyridiniomethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-2-oxoethylidene]amino]oxy]propyl]amino]carbonyl]-26-decarboxy- 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-5-chloro-1,3-thiazol-4-yl)-2-[(3-{[(1S,2R,18R,19R,22S,25R,28R,40S)-48-{[(2S,3R,4S,5S,6R)-3-{[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-22-(carbamoylmethyl)-5,47-dichloro-2,18,32,35,37-pentahydroxy-19-[(2R)-4-methyl-2-(methylamino)pentanamido]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2^{3,6}.2^{14,17}.1^{8,12}.1^{29,33}.0^{10,25}.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaen-40-yl]formamido}propoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium Phase III Skin and soft tissue infections BUILDING BLOCK Vancomycin, Formula C66H75Cl2N9O24 Molar mass 1449.27 g·mol−1 Cefilavancin (TD-1792) is an experimental antibiotic medication developed for the treatment of bacterial infections such as drug-resistant strains of Staphylococcus aureus. It is a prodrug which is also a codrug, injected intravenously …
Levacetylleucine
It’s only fair to share… Levacetylleucine WeightAverage: 173.212Monoisotopic: 173.105193347 Chemical FormulaC8H15NO3 (2S)-2-acetamido-4-methylpentanoic acid FDA APPROVED 9/24/2024, To treat Niemann-Pick disease type CPress ReleaseDrug Trials Snapshot Registered Niemann-Pick disease type C 18 Mar 2025Phase-III clinical trials in Ataxia telangiectasia (In adolescents, In children, In the elderly, In adults) in Switzerland, Slovakia, Spain, Germany, USA, United Kingdom …
Canlitinib
It’s only fair to share… Canlitinib Cas 2222730-78-9 Molecular Weight 619.61 Formula C33H31F2N3O7 6-[4-[2-fluoro-4-[[1-[(4-fluorophenyl)carbamoyl]cyclopropanecarbonyl]amino]phenoxy]-6-methoxyquinolin-7-yl]oxyhexanoic acid CANLITINIB is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication. Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study. Kanitinib is a tyrosine kinase inhibitor targeting the oncoprotein …
BRIGIMADLIN
It’s only fair to share… BRIGIMADLIN Cas 2095116-40-6 WeightAverage: 591.46Monoisotopic: 590.1287742 Chemical FormulaC31H25Cl2FN4O3 9A934ZAN94 Spiro[3H-indole-3,2′(1′H)-pyrrolo[2′,3′:4,5]pyrrolo[1,2-b]indazole]-7′-carboxylic acid, 6-chloro-3′-(3-chloro-2-fluorophenyl)-1′-(cyclopropylmethyl)-1,2,3′,3′a,10′,10′a-hexahydro-6′-methyl-2-oxo-, (2′S,3′S,3′aS,10′aS)- (2′S,3′S,3′aS,10′aS)-6-Chloro-3′-(3-chloro-2-fluorophenyl)-1′-(cyclopropylmethyl)-1,2,3′,3′a,10′,10′a-hexahydro-6′-methyl-2-oxospiro[3H-indole-3,2′(1′H)-pyrrolo[2′,3′:4,5]pyrrolo[1,2-b]indazole]-7′-carboxylic acid ( Brigimadlin (BI-907828) is a small molecule MDM2–TP53 inhibitor developed for liposarcoma.[2][3][4][5][6] Brigimadlin is an orally available inhibitor of murine double minute 2 (MDM2), with potential antineoplastic activity. Upon oral administration, brigimadlin binds to MDM2 protein and prevents its binding …